Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell lymphoma (MCL) are addressing unmet needs by providing novel therapeutic options, and explore how the integration of these therapies into current chronic lymphocytic leukemia (CLL) and MCL treatment guidelines could reshape management strategies, with consideration given to factors such as efficacy, safety, and patient access.

EP: 1.Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP: 2.Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP: 3.Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

Now Viewing

EP: 4.Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

Video content above is prompted by the following:

1. What are the clinical implications of these trials, and which unmet needs are being addressed or potentially fulfilled in the MCL landscape?
2. In the context of the evolving treatment landscape, how do you envision the integration of emerging BTKi therapies impacting current treatment guidelines for CLL and MCL? What factors should be considered?

Related Videos